[Tardive Dyskinesia induced by neuroleptics: a survey of 3140 patients in a psychiatric hospital]. 1977

M Bourgeois

Tardive dyskinesia constitute the most serious complications of long term treatment with neuroleptics. In this study e,140 patients (1,568 men, 1,572 women) were examined in 4 psychiatric hospitals. 258 (8.2%) patients were found to present such a syndrom. The frequency of tardive dyskinesia was higher among female patients (167 women; 10.6%) than among male patients (91; 5.8%). On the average dyskinetic women were older than men (64.9 versus 54 years old). In 59.3% of the cases, dyskinesia was limited to an oro-facial symptomatology, but in 40.6% of the cases, this was associated with a choreo-athetoïd syndrom. Most of these patients were chronic patients. On the average they had been in hospital for 20 years, and had received neuroleptic treatment for 15 years. In half of the patients, the treatment was undergone for schizophrenia and chronic delusion. Other syndroms encountered were mental retardation, dementia, affective disorders, epilepsy, alcoholism, character disorders, etc... The frequency of tardive dyskinesia that we observed is certainly a minimum since there exits a number of transient pathological forms. We discuss a few aspects of treatments of tardive dyskinesia with neuroleptics, lithium, diethylaminoethanol, choline... we insist particularly on the problem of prevention. In patients treated with neuroleptics, tardive dyskinesea might be stopped at an early stage: secondary prevention, consisting in an early detection of the first symptoms of lingual or facial dyskinesia, should lead, if possible, to the withdrawal of the treatment. Primary prevention appears to be very important: the risk of drug-induced dyskinesia appears to be higher among people above 50 of age, and neuroleptic treatment should be administered only for the most serious forms of mental illnesses.

UI MeSH Term Description Entries
D007049 Iatrogenic Disease Any adverse condition in a patient occurring as the result of treatment by a physician, surgeon, or other health professional, especially infections acquired by a patient during the course of treatment. Hospital-Acquired Condition,Condition, Hospital-Acquired,Conditions, Hospital-Acquired,Disease, Iatrogenic,Diseases, Iatrogenic,Hospital Acquired Condition,Hospital-Acquired Conditions,Iatrogenic Diseases
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon

Related Publications

M Bourgeois
December 1979, The British journal of psychiatry : the journal of mental science,
M Bourgeois
January 1987, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines,
M Bourgeois
December 1977, The American journal of psychiatry,
M Bourgeois
January 1984, Rivista di neurologia,
M Bourgeois
December 1982, Clinical neuropharmacology,
M Bourgeois
August 1979, Biological psychiatry,
M Bourgeois
February 1992, Clinical neuropharmacology,
M Bourgeois
October 1982, Journal of clinical psychopharmacology,
Copied contents to your clipboard!